Synapse - Hematologic Malignancies, Division of

Results (13379)

ITIL-306-201: A multicenter, first-in-human phase 1a/1b study of ITIL-306, an engineered autologous tumor-infiltrating lymphocyte (TIL) cell therapy product, in adults with advanced solid tumor

Meeting Abstract

Ward, J.; Ghobadi, A.; Liao, J.; Schoenfeld, A.; Tykodi, S.; Jiang, Y.; Le Gall, J.; Alvarez-Rodriguez, R.; Sherman, M.; Singson, T.; more...
Journal for ImmunoTherapy of Cancer (2022)

Fulltext@MSK | Save

Initial results from a phase 1a/b study of IK-175, an oral AHR inhibitor, as a single agent and in combination with nivolumab in patients with advanced solid tumors and urothelial carcinoma

Meeting Abstract

Aggen, D.; McKean, M.; Lakhani, N.; Bashir, B.; Hoffman-Censits, J.; Alhalabi, O.; Guancial, E.; Bowman, I.; Tan, A.; Lingaraj, T.; more...
Journal for ImmunoTherapy of Cancer (2022)

Fulltext@MSK | Save

First-line avelumab treatment in patients with metastatic Merkel cell carcinoma: 4-year follow-up from the JAVELIN Merkel 200 trial

Meeting Abstract

D'Angelo, S.; Lebbé, C.; Mortier, L.; Brohl, A.; Fazio, N.; Grob, J. J.; Prinzi, N.; Hanna, G.; Hassel, J.; Kiecker, F.; more...
Journal for ImmunoTherapy of Cancer (2022)

Fulltext@MSK | Save

Repeat dosing of oncolytic adenovirus ONCOS-102 is associated with enhanced and persistent immune responses and improved systemic activity in anti-PD-1 resistant/refractory (R/R) melanoma

Meeting Abstract

Shoushtari, A.; Ottesen, L.; Levitsky, V.; Hansen, T. B.; Hornyak, T.; Olszanski, A.; Nyakas, M.; Wolchok, J.
Journal for ImmunoTherapy of Cancer (2022)

Fulltext@MSK | Save

Post-hoc analysis from two phase I/II NY-ESO-1-TCR T-cell therapy clinical trials in patients with advanced sarcoma (SS or MRCLS) demonstrates response across a range of NY-ESO-1 expression

Meeting Abstract

Klohe, E.; Suchindran, S.; Kapoor, G.; D'Souza, J.; Corigleano, E.; Araujo, D.; D'Angelo, S.
Journal for ImmunoTherapy of Cancer (2022)

Fulltext@MSK | Save

Biomarker correlates of letetresgene autoleucel (lete-cel; GSK3377794) response in patients with advanced myxoid/round cell liposarcoma (MRCLS)

Meeting Abstract

Kapoor, G.; Zajic, S.; Suchindran, S.; Kim, J.; Saxena, U.; Bhaskar, A.; Kaczynski, H.; Nathenson, M.; D'Souza, J.; Rich, B.; more...
Journal for ImmunoTherapy of Cancer (2022)

Fulltext@MSK | Save

Immunogenic landscape and therapeutic targeting of mutant NRAS "public" neoantigens

Meeting Abstract

Etxeberria, I.; Banks, L.; Chandran, S.; Correa, A.; Novak, B.; Fleischman, J.; Drilon, A.; Wolchok, J.; Merghoub, T.; Klebanoff, C.
Journal for ImmunoTherapy of Cancer (2022)

Fulltext@MSK | Save

Efficacy and safety of parsaclisib-ruxolitinib combination therapy in myelofibrosis patients (Pts) with low vs higher baseline platelet count (PC): A subgroup analysis of data from a phase 2 study

Meeting Abstract

Yacoub, A.; Borate, U.; Rampal, R.; Ali, H.; Wang, E.; Gerds, A.; Hobbs, G.; Kremyanskaya, M.; Winton, E.; O'Connell, C.; more...
Cancer Research (2022)

Fulltext@MSK | Save

Pharmacokinetic (PK) profile of a novel IKZF1/3 degrader, CFT7455, enables significant potency advantage over other IKZF1/3 degraders in models of multiple myeloma (MM) and the results of the initial treatment cohort from a first-in-human (FIH) phase 1/2 study of CFT7455 in MM

Meeting Abstract

Lonial, S.; Richard, S.; Matous, J. V.; Yee, A. J.; Shah, U.; Mehta-Shah, N.; Martin, T.; Muchtar, E.; Ailawadhi, S.; Richardson, P. G.; more...
Cancer Research (2022)

Fulltext@MSK | Save

Higher levels of circulating exhausted T-cells at pre- and post-infusion negatively associated with clinical efficacy in tisagenlecleucel (Tisa-cel) treated relapsed/refractory large B-cell lymphoma (r/r LBCL) patients (pts) in JULIET trial

Meeting Abstract

Jäger, U.; Han, X.; Germano, D.; Quinn, D.; Gaddis, D.; Masood, A.; Mulvey, T.; Mataraza, J.; Bishop, M. R.; Salles, G.; more...
Cancer Research (2022)

Fulltext@MSK | Save